26 May 2020

The Radboud Biobank has added one new sub-biobank to the collection: HEMLYM.

The Hematology-Lymphoma Biobank plans to collect blood, saliva, serum and cell-free DNA from every lymphoma patient, in addition to the residual material available from the Pathology department (tumor tissue), the Hematology department and the Laboratory of Hematology (bone marrow, peripheral blood and tumor tissue). In recent years, much progress has been made in the knowledge surrounding the processes involved in the development and progression of lymph node cancer and the response to therapy. The aim and ambition of HEMLYM is to improve the diagnosis and treatment of patients with lymphoma.
 
  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud biobank

Related news items


One year since the new business model for the Radboud Biobank was implemented

3 March 2026

The new business model was introduced last year, with departments paying half of the biomaterial processing costs, covering the storage costs, and applying a graduated rate for sample issuance.

go to page

Periodic invoicing biobank collections

3 March 2026

Since 2025, the Radboud Biobank periodically charges all biobank collections for the processing and storage costs incurred.

go to page

The purpose of a central biobank facility such as the Radboud Biobank

3 March 2026

As the central biobank facility of Radboudumc, the Radboud Biobank does more than simply store human biomaterials.

go to page

Radboud Biobank's 2025 annual report

3 March 2026

The Radboud Biobank's 2025 annual report is now available on request.

go to page

Aevai Health developed a virtual assistant

3 March 2026

Aevai Health has developed Alva - a virtual assistant to engage research participants, which can support participants with health literacy, understanding research protocols, and with using measurement devices.

go to page

Radboudumc Researchers Highlight Critical Gaps in Reporting Pre-Analytical Processes in Biobanked Biomaterials

21 October 2025

Radboudumc Researchers have identified significant shortcomings in pre-analytical sample processing reporting in clinical biomarker research, a factor crucial for study reliability and replicability.

go to page